Contact Information
Stephen J. Forman, M.D., F.A.C.P.
  • Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation
  • Co-leader, Hematologic Malignancies Program
  • Associate Director for Clinical Sciences
  • Professor, Hematology & Hematopoietic Cell Transplantation
  • Professor, Medical Oncology & Therapeutics Research
  • Clinical Director, Cancer Immunotherapeutics & Tumor Immunology

Primary Specialties

Departments/Division/Program
  • Hematology & Hematopoietic Cell Transplantation
  • Hematologic Malignancies
  • Cancer Immunotherapeutics & Tumor Immunology
  • Medical Oncology & Therapeutics Research

Biography

 
Stephen J. Forman, M.D., F.A.C.P., is the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and an international expert in leukemia, lymphoma and bone marrow transplantation. Dr. Forman is also the program leader for City of Hope’s NCI-designated Comprehensive Cancer Center’s Hematologic Malignancies Program as well as its associate director for clinical sciences.

Prior to joining City of Hope in 1978, Dr. Forman earned his bachelor’s degree, cum laude, in philosophy from St. John’s College in Annapolis, Maryland, and his medical degree with honors from the University of Southern California. He interned and served his residency in internal medicine at Harbor General-University of California Los Angeles Hospital, after which he completed fellowships in hematology at Los Angeles County-University of Southern California Medical Center and in medical oncology at City of Hope.

Dr. Forman is a member of several national organizations and also serves on the editorial boards of many scientific journals. He was recently appointed to the Strategic Planning Advisory Committee of the California Institute of Regenerative Medicine. He is co-editor of Thomas’ Hematopoietic Cell Transplantation, a definitive textbook for scientists and health care professionals.

Professional Experience

 
  • 2014 - present, Associate Director for Clinical Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2004 - present, Director of Clinical Research, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 1987 - present, Co-leader, Hematologic Malignancies Program, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 1987 - present, Chair, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 1980 - present, Staff Physician, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA
  • 1979 - present, Staff Physician, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 1979 - 1980, Fellow, Medical Oncology, City of Hope, Duarte, CA
  • 1978 - 1979, Research Associate, Hematology Division, Department of Pharmacology, LAC/USC Medical Center, Los Angeles, CA
  • 1976 - 1978, Fellow, Hematology Division, LAC/USC Medical Center, Los Angeles, CA
  • 1974 - 1976, Intern and resident, Internal Medicine, Harbor UCLA Hospital, Torrance, CA

Education

 
Education/Training
  • 1974, University of Southern California, Los Angeles. M.D. Medicine (AOA)
  • 1970, St. John's College, Annapolis, B.A. Philosophy, cum laude
 

Honors/Awards

 
Awards
  • 2006 - present, Francis and Kathleen McNamara Distinguished Chair in Hematology & Hematopoietic Cell Transplantation

Honors
  • 1992 - present, Best Doctors in America®
  • 1992, City of Hope Gallery of Medical and Scientific Achievement
 

Publications


  • Blume, K.G., Forman, S.J. and Appelbaum, F.R. Editors. Hematopoietic Cell Transplantation, 3rd edition. London: Blackwell Publishing Ltd., London, England 2004.
  • Nademanee A, Forman SJ. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Semin Hematol. 2006 Oct;43(4):240-50. Review.
  • Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, Gonzalez N, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia. 2006 Oct;20(10):1889-92. No abstract available
  • Lacey SF, La Rosa C, Zhou W, Sharma MC, Martinez J, Krishnan A, Gallez-Hawkins G, Thao L, Longmate J, Spielberger R, Forman SJ, Limaye A, Zaia JA, Diamond DJ. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis. 2006 Nov 15;194(10):1410-21. Epub 2006 Oct 11.
  • Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S, Vora N, Gaal K, Nakamura R, Forman SJ. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant. 2006 Nov;12(11):1161-8.
  • Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006 Nov 15;66(22):10995-1004.
  • Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34.
  • Zhang, C., Todorov, I., Zhang, A., Liu, Y., Kandeel, F., Forman, S., Strober, S., Zeng, D. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood, 107:2993-3001, 2006.
  • Nademanee, A., Forman, S.J., Molina, A., Fung, H., Smith, D., Dagis, A., Kwok, C., Yamauchi, D., Anderson, A., Falk, P., Krishnan, A., Kirschbaum, M., Kogut, N., Nakamura, R., O’Donnell, M., Parker, P., Popplewell, L., Pullarkat, V., Rodriguez, R., Sahebi, F., Smith, E., Snyder, D., Stein, A., Spielberger, R., Zain, J., White, C., and Raubitschek, A. A phase ½ trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood, 106:2896, 2005.
  • Cooper, L.J., Al-Kadhimi, Z., Serrano, L.M., Pfeiffer, T., Olivares, S., Castro, A., Chang, W.C., Gonzalez, S., Smith, D., Forman, S.J., and Jensen, M.C. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood, 105:1622, 2005.
  • Krishnan, A., Molina, A., Zaia, J., Smith, D., Vasquez, D., Kogut, N., Falk, P.M., Rosenthal, J., Alvarnas, J., and Forman, S.J. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood, 105:874, 2005.
  • Stein, A.S., O’Donnell, M.R., Slovak, M.L., Snyder, D.S., Nademanee, A.P., Parker, P., Molina, A., Somlo, G., Fung, H.C., Krishnan, A., Rodriguez, R., Spielberger, R.T., Wang, S., Dagis, A., Vora, N., Arber, D.A., Niland, J.C., Forman, S.J. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. Journal of Clinical Oncology, 21:615, 2003.
  • Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., Arber, D.A., Slovak, M.L., and Forman, S.J. Persistence of malignant Hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101:4701, 2003.
  • Shih, C., Weng, Y., Mamelak, A., LeBon, T. and Forman, S.J. Identification of a candidate human neurohematopoietic stem-cell population. Blood, 98:2412, 2001.
  • Gillies, S., Lan, Y., Williams, S., Carr, F., Forman, S.J., Raubitschek, A. and Lo, K.M. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood, 105:3972-78, 2005.
  • Holtz, M.S., Forman, S.J. and Bhatia, R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia, 19:1034-41, 2005.
  • Lacey, S.F., Martinez, J., Gallez-Hawkins, G., Thao, L., Longmate, J., Haq, W., Spielberger, R., Forman, S.J., Zaia, J. and Diamond, D. Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem cell transplant recipients. Journal of Infectous Disease, 191:977-84, 2005.
  • Cooper, LJN., Al-Kadhimi, Z., Serrano, L., Pfeiffer, T., Olivares, S., Castro, A., Chang, W-C., Gonzalez, S., Smith, D., Forman, S.J., and Jensen, M.C. Enhanced anti-lymphoma efficacy of CD-19 redirected influenza-specific CTL’s by co-transfer of t-cells modified to express influenza MP-1. Blood, 105:1622-31, 2005.
  • Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101:4701-7, 2003.
  • Cooper, L.J.N., Topp, M.S., Serrano, L.M., Gonzalez, S., Chang, W.-C., Wright, C., Popplewell, L., Raubitschek, A., Forman, S.J., and Jensen, M.C. T cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft versus B-lineage leukemia effect. Blood, 101:1637-44, 2003.
  • Stein, A.S., O’Donnell, M.R., Slovak, M.S., Snyder, D., Nademanee, A., Parker, P., Molina, A., Somlo, G., Fung, H.C., Krishnan, A., Rodriguez, R., Spielberger, R.T., Wang, S., Dagis, A., Vora, N., Arber, D.A., Niland, J.C. and Forman, S.J. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J of Clinical Oncology, 21:615-23, 2003.
  • Bensinger, W., Martin, P., Storer, B., Clift, R., Forman, S.J., Negrin, R., Kashyap, A., Flowers, M.E.D., Lilleby, K., Chauncey, T.R., Storb, R. and Appelbaum, F.R. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic malignancies. NEJM, 344:175-181, 2001.

Locations


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010